🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

382 results for “Ology” Clear

  1. SC291

    Sana Biotechnology

    Lupus Erythematosus

    phase 1 mab active

    1 trial

  2. SC291

    Sana Biotechnology

    Non Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

  3. SRF617

    Coherus Oncology

    Advanced Solid Tumor

    phase 1 small molecule completed

    1 trial

  4. Sotrovimab

    Vir Biotechnology

    COVID-19 Infection

    phase 1 mab terminated

    1 trial

  5. Study of DFF332 alone and in combination with Everolimus or Immuno-oncology therapies in patients with renal cell carcinoma and other selected tumors.

    Novartis Pharmaceuticals

    Advanced, relapsed Clear Cell Renal Cell Carcinoma

    phase 1 other active

    1 trial

  6. TAK-114 10 mg capsule

    Takeda

    Clinical Pharmacology

    phase 1 small molecule completed

    1 trial

  7. TAK-233

    Takeda

    Clinical Pharmacology

    phase 1 small molecule completed

    1 trial

  8. Tipifarnib

    Kura Oncology

    Advanced Solid Tumor

    phase 1 small molecule terminated

    1 trial

  9. Tipifarnib

    Kura Oncology

    NSCLC

    phase 1 small molecule terminated

    1 trial

  10. UP421

    Sana Biotechnology

    Type1diabetes

    phase 1 mab active

    1 trial

  11. VIR-1111

    Vir Biotechnology

    HIV I Infection

    phase 1 mab completed

    1 trial

  12. VIR-2218

    Vir Biotechnology

    Hepatic Impairment

    phase 1 small molecule active

    1 trial

  13. VIR-2218

    Vir Biotechnology

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  14. VIR-2482

    Vir Biotechnology

    Influenza A

    phase 1 small molecule completed

    1 trial

  15. VIR-3434

    Vir Biotechnology

    Chronic Hepatitis B

    phase 1 mab completed

    1 trial

  16. VIR-5500

    Vir Biotechnology

    Hormone-refractory Prostate Cancer

    phase 1 small molecule active

    1 trial

  17. VIR-5525

    Vir Biotechnology

    Solid Tumor Malignancies

    phase 1 small molecule active

    1 trial

  18. VRON-0200-AdC6

    Vir Biotechnology

    Chronic Hepatitis B

    phase 1 mab active

    1 trial

  19. Venetoclax

    Kura Oncology

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  20. Ziftomenib

    Kura Oncology

    KMT2A-rearranged

    phase 1 small molecule active

    1 trial

  21. Ziftomenib

    Kura Oncology

    AML

    phase 1 small molecule active

    1 trial

  22. Ziftomenib

    Kura Oncology

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  23. Ziftomenib

    Kura Oncology

    Refractory Acute Leukemia

    phase 1 small molecule active

    1 trial

  24. Ziftomenib

    Kura Oncology

    Relapsed/Refractory KMT2A-r Acute Leukemia

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources